Geno Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 1.10%
- Profit Growth -90.53%
- Ebitda -67.08%
- Net Worth 4.56%
- Total Assets 23.71%
About Geno Biosciences
Geno Biosciences Private Limited (GBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 03 October 2005 and has a history of 19 years and four months. Its registered office is in Delhi, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Aftab Alam, Tariq Kamal, Mohmmad Khan, and One other member serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74899DL2005PTC141378
-
Company No.
141378
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Oct 2005
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Geno Biosciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tariq Kamal
|
Whole-Time Director | 02-Apr-2018 | Current |
Aftab Alam
|
Director | 03-Oct-2005 | Current |
|
Mohmmad Khan
|
Whole-Time Director | 04-Apr-2019 | Current |
|
Mohhmad Parvej
|
Whole-Time Director | 04-Apr-2019 | Current |
Financial Performance of Geno Biosciences.
Geno Biosciences Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.1% increase. The company also saw a substantial fall in profitability, with a 90.53% decrease in profit. The company's net worth moved up by a moderate rise of 4.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Geno Biosciences?
In 2023, Geno Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Tecziq Solutions Private LimitedTariq Kamal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Geno Biosciences?
Geno Biosciences has a workforce of 20 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geno Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geno Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
